Tian Yun

Tian Yun

Auto-generated profile, based on publicly available information

Tian Yun

Department of Pathology, The 989th Hospital of the PLA Joint Logistic Support Force, Luoyang 471031, China

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011 in Molecular Cytogenetics
Verified
Journal Article
Open access
PDF file
WYWang Yk
Wang Yk
GCGao Cf
Gao Cf
YTYun T
Yun T
CZChen Z
Chen Z
ZXZhang Xw
Zhang Xw
ZWZhao Wz
Zhao Wz
The goal of this study was to investigate ERBB2(HER2) and EGFR gene amplification and protein expression in gastric cancer. Fluorescence in situ hybridization (FISH) and immunohistochemistry were used to analyze ERBB2 and EGFR gene amplification and protein expression in 69 cases of gastric cancer.

13 October 2020 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
TYTian Yun
Tian Yun
SWSunan Wang
Sunan Wang
BJBo Jiang
Bo Jiang
CWChangsong Wang
Changsong Wang
NMNianlong Meng
Nianlong Meng
YWYangkun Wang
Yangkun Wang
Objective. To explore the relationship between the HER2 gene and PD-1/PD-L1 in gastric cancer and its significance. Methods. Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) were used to detect HER2 protein expression, HER2 gene amplification, and PD-1/PD-L1 expression in 78 cases of gastric cancer. Results. The expression rate of HER2 protein was 43.6% (34/78), of which 19.4% (14/78) were HER2 3+, 14.1% (11/78) were HER2 2+, and 11.5% (9/78) were HER2 1+. The results showed that 19.2% (15/78) of samples had HER2 gene amplification, 3.8% (3/78) of samples had a HER2/CEP17 ratio <2.0, and 19.2% (15/78) of samples had HER2 gene amplificationf and HER2 copy/cell ≥6.0, as detected by FISH. The positive rate of PD-L1 was 38.5% (30/78) in gastric cancer cells and 50.0% (39/78) in interstitial lymphocytes. The expression of the HER2 gene, PD-L1, and PD-1 in gastric cancer was correlated with the stage and lymph node metastasis of gastric cancer ( P < 0.05 ). Conclusions. The combined detection of the HER2 gene and PD-1/PD-L1 in gastric cancer provides an important reference index for the prognosis of gastric cancer and the benefit of targeted antitumor drugs.

6 February 2018 in Cancer Biomarkers
Verified
Journal Article
Closed access
PDF file
YWYang-Kun Wang
Yang-Kun Wang
SWSu-Nan Wang
Su-Nan Wang
YLYing-Ying Li
Ying-Ying Li
GWGong-Ping Wang
Gong-Ping Wang
TYTian Yun
Tian Yun
MZmeiling Zhu
meiling Zhu
OBJECTIVE: This study aims to investigate the significance of combined detection of HER2 gene amplification and chemosensitivity in gastric cancer. METHODS: Immunohistochemistry (IHC), fluorescence in situ hybridization (FISH) and fluorescence revers

28 May 2025 in BMC Cancer
Verified
Journal Article
Open access
PDF file
XLXuexia Lv
Xuexia Lv
JCJingChang Chen
JingChang Chen
XLXuexia Lv
Xuexia Lv
TYTian Yun
Tian Yun
YWYaxi Wang
Yaxi Wang
XWXiaoyue Wang
Xiaoyue Wang
The Ki-67 index, which is a proliferative index, has become more important in making treatment decisions for patients with breast cancer (BC) and plays both a predictive role and a prognostic role. However, a few factors limit its use in clinical practice, particularly the assessment of the percentage of Ki-67-positive cells and the cutoff value of Ki-67. In this study, we examined the expression of Ki-67 via immunohistochemistry and systematically evaluated the value of the Ki-67 index in patients with BC. This was a retrospective study including 280 patients diagnosed with BC. There were marked differences in overall survival (OS) between patients with BC when the Ki-67 index ranged from 46 to 68% (χ2 = 5.87, P = 0.0154; χ2 = 7.64, P = 0.0057, respectively), and the same results were also found when the staining density was added to the Ki-67 index; however, the staining density alone has limited value in assessing the value of Ki-67. There were marked differences in disease-free survival (DFS) among BC patients when the Ki-67 index ranged from 50 to 58% (χ2 = 7.31, P = 0.0069; χ2 = 7.88, P = 0.005). When 14% was used as a cutoff point to classify the molecular type of BC, the luminal A-type patients were significantly different from patients with HER2-overexpressing subtype BC in terms of OS (χ2 = 5.33, P = 0.021). There was a significant difference in the OS of patients with human epidermal growth factor receptor 2 (HER-2)-overexpressing subtype BC when the Ki-67 index fell within the range of 49-60% (χ2 = 4.86, P = 0.0275; χ2 = 5.50, P = 0.019, respectively). There were significant differences between luminal A-type BC and HER2-overexpressing subtype BC in terms of OS (χ2 = 5.53, P = 0.019), according to suggestions of the 2019 CSCO consensus. There were significant differences between the two groups of luminal B HER-2(-) BC when the Ki-67 index was 52% (χ2 = 6.61, P = 0.0101). The differentiated Ki-67 index can be used to assess the OS and DFS of patients with BC, and the staining density of Ki-67 has little value in assessing prognosis in these patients. Different molecular classification methods may influence the assessment of prognosis and the results of molecular subtype in patients with BC. To predict the prognosis of BC patients, it is more scientifically feasible to use the interval values of Ki-67 than a specific value.

7 May 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
XLXuexia Lv
Xuexia Lv
NFNaijun Fan
Naijun Fan
TYTian Yun
Tian Yun
FLFulin Li
Fulin Li
NMNianlong Meng
Nianlong Meng
XLXuexia Lyu
Xuexia Lyu
Objectives: Langerhans cell sarcoma (LCS) is a very rare, highly malignant tumor that originates from Langerhans cells. The differential diagnosis of LCS and Langerhans cell histiocytosis (LCH) still faces limitations, and the molecular changes involved in LCS are unclear. Molecular biomarkers and immunophenotypes may help distinguish between LCS and LCH. In this manuscript, the pathological and molecular markers in LCS are explored. Methods: The expression patterns of ASPP1, ASPP2, and inhibitor of apoptosis-stimulating p53 protein (iASPP) were examined using the immunohistochemical method and immunofluorescence staining. Then, genetic features, such as B-Raf proto-oncogene, serine/threonine kinase (BRAF) V600E, K-ras, and ROS proto-oncogene 1, receptor tyrosine kinase (ROS1), were assayed using the amplification refractory mutation system (ARMS) method. Finally, whole-exon sequencing of LCS was performed. Results: Immunohistochemically, in all samples of LCS, ASPP2 was detected in ovoid and elliptic tumor cells. In the case of LCH, ASPP2 was expressed not only in ovoid and elliptic cells but also in histiocytic cells. The expression of iASPP was observed in five cases LCS (5/6), and no positive reaction was observed in the case of LCH. No ASPP1 expression was observed in LCH and LCS. During triple-color immunofluorescence analysis, ASPP2 and iASPP were co-expressed on Langerin+ LCS tumor cells. No mutations of BRAF V600E, K-ras, or ROS1 were detected in LCH and LCS. No gene mutation or rearrangement was detected in LCS except for the MAP2K1 gene. The mutation site was nonsynonymous in 607 bp of MAP2K1, resulting in a change from base G to A; thus, the amino acid E changed to K at the 203 site (4/6, 66.67%). Conclusions: Combined detection of ASPP2 and iASPP in tissue samples may provide valuable markers to differentiate between LCH and LCS. The MAP2K1 variants c.607G > A is the first potential marker to be reported in LCS.